WHO: “Preliminary laboratory-based studies indicate a relative growth advantage of BA.2.75 as compared to BA.2 and BA.5. Further, there is an indication of higher fusogenicity, more efficient replication in lung … Continue reading WHO: BA.2.75 has more efficient replication in lung cells, fusogenicity, pathogenicity